health insurance

The Vitality Re series of health insurance-linked securities (ILS) transactions, which provide reinsurance protection to health insurer Aetna, are exposed to potential triggering by the coronavirus pandemic should it result in “severe morbidity stress”, rating agency S&P has said.

Aetna, the health, medical and benefits insurance arm of CVS Health, is set to secure its latest and eleventh insurance-linked securities (ILS) transaction Vitality Re XI Ltd. (Series 2020) at attractive pricing, as both tranches saw their respective coupons price down roughly 25%.

The price guidance has fallen for both of the tranches of notes to be issued as part of Aetna’s latest insurance-linked securities (ILS) transaction Vitality Re XI Ltd. (Series 2020) signalling strong investor appetite for what has become an annual diversifying peril for some investors in the sector.

Aetna, the health, medical and benefits insurance arm of CVS Health, has returned to the insurance-linked securities (ILS) market for its eleventh Vitality Re transaction (Vitality Re XI Ltd. (Series 2020)), as it continues to leverage the capital markets as a source of reinsurance capital.

Aetna, the health, medical and benefits insurance arm of CVS Health, has successfully completed its latest and tenth trip to the catastrophe bond and insurance-linked securities (ILS) market for collateralized reinsurance, with its $200 million Vitality Re X Ltd. (Series 2019) deal.

Health insurance giant Aetna will be delighted with the response from ILS investors to its latest and tenth health or medical benefit risk ILS transaction, the $200 million Vitality Re X Ltd. (Series 2019) deal, as pricing falls to the bottom of initial guidance.

Health insurance giant Aetna is returning to the capital markets and insurance-linked securities with what will be its tenth health or medical benefit risk ILS transaction, a $200 million Vitality Re X Ltd. (Series 2019) deal.

Health care benefits insurer Aetna has successfully completed its ninth capital markets backed reinsurance arrangement through a $200 million issuance of health insurance-linked securities (ILS), in the Vitality Re IX Ltd. (Series 2018-1) transaction.

The $200 million Vitality Re IX Ltd. (Series 2018-1) health insurance-linked securities (ILS) transaction from Aetna has now been priced and both tranches of notes have had their coupons fixed at levels below the bottom-end of the initial price guidance ranges.

Pricing for the in-the-market $200 million Vitality Re IX Ltd. (Series 2018-1) health insurance-linked securities (ILS) issuance has been delayed due to uncertainty over the future of health insurer fees, because the U.S. government has been considering the fees as part of government shutdown related budgetary debates.